Attached files
| file | filename |
|---|---|
| EX-8.1 - EX-8.1 - Hepion Pharmaceuticals, Inc. | a2236007zex-8_1.htm |
| EX-1.1 - EX-1.1 - Hepion Pharmaceuticals, Inc. | a2236007zex-1_1.htm |
| S-1/A - S-1/A - Hepion Pharmaceuticals, Inc. | a2236007zs-1a.htm |
QuickLinks -- Click here to rapidly navigate through this document
Consent of Independent Registered Public Accounting Firm
ContraVir
Pharmaceuticals, Inc.
Edison, New Jersey
We hereby consent to the incorporation by reference in the Prospectus constituting a part of this Registration Statement of our report dated March 23, 2018 and our report dated September 28, 2017, relating to the consolidated financial statements of ContraVir Pharmaceuticals, Inc., which are incorporated by reference in that Prospectus. Our reports on the consolidated financial statements contain an explanatory paragraph regarding the Company's ability to continue as a going concern.
We also consent to the reference to us under the caption "Experts" in the Prospectus.
/s/ BDO USA, LLP
Woodbridge, New Jersey
June 12, 2018